通过非炎症性脂质纳米颗粒静止肺累积的素5AC,用于喘治疗
Zhiqiang Zhao1,2,3, Xinzhu Shan2,3, Weixue Wang2,3
1Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
ACS nano
|March 9, 2026
概括
研究人员开发了非炎症性脂质纳米颗粒 (LNP),用于输送siRNA治疗与Mucin 5AC (MUC5AC) 相关的肺部疾病. 这种新的LNP配方有效地使MUC5AC沉默,减少了喘模型中的呼吸道炎症和阻塞.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 呼吸系统医学 呼吸系统医学
背景情况:
- 素5AC (MUC5AC) 的过度表达会导致严重喘和粘液阻塞性肺部疾病 (MOLDs) 的粘液阻塞.
- 标准的脂质纳米颗粒 (LNP) 可以矛盾地增加MUC5AC由于炎症副作用.
- siRNA输送为MOLDs提供了一个潜在的治疗策略.
研究的目的:
- 设计和开发非炎症性LNP,以有效地传递siRNA来治疗MUC5AC驱动的肺部疾病.
- 为了克服与传统LNP载体相关的炎症副作用.
- 为喘和MOLDs创建一个临床可翻译的siRNA输送平台.
主要方法:
- 开发出具有较低免疫原性的可电离性化脂质,并将抗炎天然化合物纳入LNP中.
- 通过降低N/P比率来优化LNP配方,并选基因沉默效率,物理化学性质和生物安全性.
- 使用了体外和体内模型,包括室内灰尘虫 (HDM) 诱导的喘小鼠和COPD患者衍生器官.
主要成果:
- 确定了一种主要候选配方 (配方1),在体内实现85%的MUC5AC沉默,超过了基准siRNA.
- 与SM102和MC3 LNP相比,显著改善了生物安全性.
- 在喘小鼠中有效缓解呼吸道炎症和阻塞,并具有持续的预防作用.
结论:
- 使用优化的LNP开发了一个新的,非炎症性siRNA输送平台.
- 配方1通过有效抑制MUC5AC.显示了治疗喘和MOLDs的显著治疗潜力.
- 该平台在临床上可翻译,并解决了呼吸系统疾病治疗的关键未满足需求.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Drugs Used in Lower Respiratory Disorders: Overview
1.4K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.4K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Antiasthma Drugs: Muscarinic Receptor Antagonists
2.0K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.0K


